Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Novartis (SWX:NOVN) has caught investor attention after a recent stretch of positive returns, with the share price up around 5% over the past month and about 11% over the past 3 months.
See our latest analysis for Novartis.
Zooming out, the recent 5.0% 1 month share price return and 11.1% 3 month share price return sit alongside a CHF115.64 share price and a 1 year total shareholder return of 32.7%. Taken together, these figures point to momentum building rather than fading.
If Novartis has you rethinking your healthcare exposure, this could be a good moment to scan other pharma names and check out pharma stocks with solid dividends.
With the share price around CHF115.64 and an intrinsic value estimate indicating a sizeable discount, the key question is whether Novartis still trades below its fundamentals or whether the market already reflects expectations for future growth.
With Novartis last closing at CHF115.64 against a widely followed fair value estimate of CHF109.99, the narrative currently points to a modest premium and a lot of moving parts behind it.
Novartis’ robust pipeline and rapid regulatory progress in advanced therapies (including biologics, gene, and cell therapies) positions the company to benefit from emerging healthcare technologies, potentially accelerating future earnings and margin growth as new high-value products launch.
Curious what earnings power justifies that fair value and premium tag? The narrative leans on steady revenue gains, fatter margins, and a future profit multiple that is framed as conservative against peers. Want to see how those pieces fit together across the next few years and what that implies for shareholder returns?
Result: Fair Value of CHF109.99 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, that narrative can quickly change if patent expiries or tougher global pricing and reimbursement decisions hit revenue and squeeze the margin story that investors are watching.
Find out about the key risks to this Novartis narrative.
While the fair value narrative points to a 5.1% premium at around CHF115.64 versus CHF109.99, the current P/E of 19.6x tells a different story. It sits below the European pharmaceuticals average of 25.3x and well under a fair ratio of 37.2x, which suggests valuation risk is not one way. Where does that leave your own comfort zone?
See what the numbers say about this price — find out in our valuation breakdown.
SWX:NOVN P/E Ratio as at Jan 2026
If you are not fully on board with this framing, or you would rather rely on your own work, you can rebuild the story yourself in just a few minutes with Do it your way.
A great starting point for your Novartis research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
If Novartis has sharpened your interest, do not stop here. Use the Simply Wall St Screener to spot other opportunities that might fit your style even better.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVN.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com